- Report
- January 2021
- 600 Pages
United States
From €2724EUR$2,800USD£2,334GBP
- Report
- November 2020
- 124 Pages
Global
From €934EUR$960USD£800GBP
€1168EUR$1,200USD£1,000GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9730EUR$10,000USD£8,335GBP
- Report
- July 2023
- 123 Pages
China
From €1751EUR$1,800USD£1,500GBP
- Report
- April 2023
- 129 Pages
Global
€4865EUR$5,000USD£4,168GBP
- Report
- April 2023
- 86 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- July 2023
- 244 Pages
China
From €3892EUR$4,000USD£3,334GBP
Triptorelin is a synthetic decapeptide agonist of the gonadotropin-releasing hormone (GnRH) receptor used in the treatment of prostate cancer. It is administered as a subcutaneous injection and works by reducing the production of testosterone, which can slow the growth of prostate cancer cells. Triptorelin is used in combination with other treatments such as radiation therapy and chemotherapy. It is also used to reduce the risk of prostate cancer recurrence after surgery.
Triptorelin is a relatively new drug in the prostate cancer market, but it has been gaining traction due to its effectiveness and convenience. It is generally well-tolerated and has fewer side effects than other treatments.
Some companies in the Triptorelin market include AbbVie, Astellas Pharma, Endo Pharmaceuticals, Ferring Pharmaceuticals, and Teva Pharmaceuticals. Show Less Read more
